How Johnson & Johnson Uses Real-World Evidence to Accelerate Clinical Research
Johnson & Johnson (J&J) is transforming the future of medical technology development by using real-world data (RWD) and real-world evidence (RWE) to improve clinical research, strengthen regulatory submissions and accelerate innovation. As healthcare systems increasingly generate vast amounts of patient information, the ability to turn this data into meaningful evidence is becoming a major competitive advantage for companies seeking faster and safer pathways to market.
For J&J, RWD and RWE are no longer supplemental research tools. They are central to how the company designs studies, evaluates patient outcomes and develops medical technologies that better reflect real-world healthcare environments. Through advanced analytics, tokenized datasets and partnerships with large healthcare databases such as the Premier Healthcare Database (PHD), the company is creating a more efficient and patient-focused approach to clinical development.
Stephen Johnston, Senior Director of Real-World Data Analytics and Research at Johnson & Johnson, believes the healthcare industry is entering a new era where data-driven evidence will play a defining role in regulatory and clinical decision-making. Having spent more than two decades in clinical research, Johnston has witnessed the evolution of evidence generation from traditional clinical trials to integrated systems powered by real-world insights.
According to Johnston, data has always been the foundation of meaningful healthcare innovation. However, recent advances in technology, data integration and analytics have significantly expanded what organizations can achieve with RWD and RWE.
The Growing Importance of Real-World Evidence
Medical device development is a highly complex process that requires balancing innovation, patient safety and regulatory compliance. Traditional clinical trials remain essential, but they often face limitations such as high costs, long timelines and challenges in recruiting representative patient populations.
To overcome these barriers, J&J is increasingly incorporating RWD into research strategies. Real-world data includes healthcare information collected outside traditional clinical trials, such as electronic medical records, billing data, insurance claims, pharmacy records and patient outcomes from routine healthcare settings. When analyzed effectively, these data generate real-world evidence that can provide valuable insights into treatment effectiveness, safety and patient experiences.
Johnston explained that RWE is becoming increasingly important for medtech regulatory approvals because it reflects how therapies and devices perform in everyday clinical practice rather than under tightly controlled trial conditions.
J&J’s broader mission is centered on improving healthcare through precision medicine and less invasive, personalized treatment approaches. The company develops technologies designed to address difficult medical challenges across multiple surgical specialties. By integrating RWE into product development and clinical research, J&J aims to shorten development timelines while improving the quality and relevance of evidence submitted to regulators.
Leveraging the Premier Healthcare Database
One of the most significant components of J&J’s RWD strategy is its collaboration with the Premier Healthcare Database. The PHD is among the largest and most comprehensive healthcare data repositories in the United States. It contains electronic medical records and chargemaster billing information from more than 1,400 hospitals and healthcare systems, covering hundreds of millions of patient records collected over two decades.
The scale of the database gives researchers access to a broad and diverse view of healthcare delivery across inpatient, outpatient and ambulatory care settings. It includes information on medications, devices, procedures, patient demographics and healthcare utilization across multiple payer types, including Medicare, Medicaid, commercial insurance and self-pay patients.
This breadth of information allows J&J researchers to analyze treatment patterns, study disease progression, evaluate healthcare economics and better understand patient outcomes in real-world settings.
The PHD also supports epidemiological studies, resource utilization analysis and financial outcomes research, helping organizations identify trends that may not be visible in smaller or more limited datasets.
The Power of Tokenization
A major innovation driving J&J’s RWD strategy is tokenization. Tokenization allows healthcare organizations to securely connect patient-level information across multiple otherwise disconnected databases while protecting patient privacy and maintaining HIPAA compliance.
According to Johnston, no single dataset can answer every research question. Different systems often contain different pieces of a patient’s healthcare journey. One dataset may include hospital encounters, while another may contain pharmacy information or genomic data. Tokenization enables these separate records to be securely linked together, creating a more complete and accurate understanding of patient experiences and outcomes.
Johnston emphasized that tokenized data helps fill important gaps in research by connecting fragmented information into a unified patient-centric view. This integrated approach allows researchers to conduct analyses that would have been extremely difficult or impossible only a few years ago.
By linking multiple sources of healthcare data, J&J can generate more reliable and fit-for-purpose evidence for regulatory submissions and post-market surveillance activities. Tokenization also helps improve the identification of eligible patient populations, track long-term outcomes and evaluate device performance across broader healthcare environments.
The ability to integrate pharmacy records, laboratory results and genomic information into clinical datasets provides additional context that can significantly strengthen evidence generation efforts.
Improving Clinical Trial Design
One of the key advantages of RWD is its ability to improve clinical trial planning and execution. Recruiting appropriate participants for clinical studies remains one of the most time-consuming and expensive aspects of medical research. In many cases, traditional trials struggle to accurately reflect the diversity and complexity of real-world patient populations.
J&J uses RWD to better understand patient demographics, comorbidities and treatment histories before launching studies. These insights help researchers design trials that more closely resemble actual clinical practice.
Johnston noted that regulators such as the U.S. Food and Drug Administration increasingly expect clinical trials to include participants who represent the real-world population likely to use the device or treatment. Ensuring demographic diversity and broader patient representation has become a major focus for healthcare companies.
By analyzing real-world populations in advance, J&J can identify appropriate inclusion criteria, optimize site selection and predict which patients are most likely to benefit from specific therapies or devices. This not only improves trial efficiency but also increases the likelihood that study findings will be relevant to routine clinical practice.
The company also uses RWD to support the development of external control arms. Instead of recruiting separate control groups for certain studies, researchers can sometimes use carefully matched real-world patient data as comparison groups, potentially reducing recruitment burdens and accelerating timelines.
Accelerating Regulatory Approvals
Regulatory agencies worldwide are showing increasing interest in the use of RWE to support healthcare product approvals and label expansions. High-quality RWE can provide evidence about long-term safety, effectiveness and real-world performance that complements traditional clinical trial data.
J&J has already achieved several regulatory successes using RWE and continues to expand its efforts in this area. Johnston described RWE as a critical component of the future regulatory landscape for medical technology companies.
Because RWD captures information from routine healthcare settings, it can provide insights into how devices perform across broader patient populations, including individuals who may not typically participate in clinical trials. This additional evidence can help regulators make more informed decisions while potentially reducing the need for lengthy or duplicative studies.
For companies, the ability to generate strong RWE may shorten development cycles, reduce costs and enable faster access to innovative treatments for patients.
Artificial Intelligence and Advanced Analytics
J&J is also exploring how artificial intelligence and large language models can further enhance the value of real-world data.
One major challenge in healthcare analytics involves hospital chargemaster data. Hospitals often use different naming conventions and descriptions for the same medical devices or procedures, making data standardization difficult.
Johnston explained that J&J is testing large language models to help interpret and organize these complex datasets more accurately. AI systems can analyze variations in device descriptions across hospitals and improve device identification, creating cleaner and more reliable datasets for research purposes.
The use of AI in RWD analysis could significantly reduce manual data processing efforts while improving the consistency and quality of evidence generation.
As machine learning technologies continue to evolve, they are expected to play an increasingly important role in identifying patterns, predicting patient outcomes and supporting precision medicine initiatives.
Supporting Patient-Centered Care
At the core of J&J’s RWE strategy is the goal of improving patient outcomes. By integrating tokenized RWD into clinical development workflows, the company aims to generate evidence that reflects the full complexity of real-world patient care.
Rather than relying solely on controlled trial environments, J&J is building systems that capture how treatments and devices perform in diverse healthcare settings across varied patient populations.
This approach helps ensure that innovations are designed not only for regulatory approval but also for practical effectiveness in everyday clinical use.
The combination of large-scale healthcare data, advanced analytics, tokenization and AI is allowing J&J to develop more personalized, evidence-based solutions for patients while helping healthcare providers make more informed treatment decisions.
About
The healthcare industry is rapidly moving toward a future where real-world evidence plays a central role in research, regulation and patient care. For Johnson & Johnson, investing in tokenized RWD and advanced analytics is helping create a more agile and efficient development process capable of delivering innovative medical technologies faster.
As healthcare datasets continue to expand and analytical technologies improve, the potential applications of RWE will likely grow even further. From optimizing clinical trials to supporting regulatory approvals and enhancing personalized medicine, RWE is becoming an essential driver of modern healthcare innovation.
For Johnston and the J&J research team, the ultimate objective is clear: use data not simply to accelerate approvals, but to improve patient outcomes and create a healthcare system that is more precise, responsive and evidence-driven.
